Table 2B.
Summary of reciprocal antibody titers to vaccination for poliovirus types 1, 2, and 3 by study arms
| Vaccine Response | Arm A | Arm B | Arm C | Arm D | Kruskal-Wallis Test | ||||
|---|---|---|---|---|---|---|---|---|---|
| IPV14+IPV booster | IPV14+fIPV booster | IPV6+fIPV booster | fIPV6/14+fIPV booster | ||||||
| (n=271) | (n=267) | (n=268) | (n=270) | ||||||
| Type 1 | |||||||||
| Vaccine response to primary series | 164 | 23 (13–57) | 141 | 23 (14–57) | 101 | 28 (14–144) | 212 | 144 (51–455) | B v A: p = 0.51 D v A, D v B: p < 0.0001 C v B: p = 0.25 |
| Priming response | 107 | ≥1448 (1152-≥1448) | 124 | 576 (288–1152) | 155 | 1152 (362-≥1448) | - | - | B v A: p < 0.0001 C v B: p = 0.0057 |
| Cumulative vaccine response | 271 | ≥1448 (1152-≥1448) | 265 | 910 (455-≥1448) | 256 | ≥1448 (576-≥1448) | - | - | B v A: p < 0.0001 C v B: p = 0.0026 |
| Vaccine response to booster | 271 | ≥1448 (724-≥1448) | 264 | 576 (228–1152) | 255 | ≥1448 (576-≥1448) | 264 | 288 (114–910) | B v A, D v A, D v B, C v B: p < 0.0001 |
| Type 2 | |||||||||
| Vaccine response to primary series | 126 | 14 (9–23) | 123 | 14 (11–23) | 70 | 14 (11–28) | 173 | 45 (18–144) | B v A: p = 0.17 D v A, D v B: p < 0.0001 C v B: p = 0.58 |
| Priming response | 143 | ≥1448 (910-≥1448) | 139 | 576 (228–910) | 167 | 724 (114-≥1448) | - | - | B v A: p < 0.0001 C v B: p = 0.62 |
| Cumulative vaccine response | 269 | ≥1448 (1152-≥1448) | 262 | 910 (362–1152) | 237 | 910 (228-≥1448) | - | - | B v A: p < 0.0001 C v B: p = 0.34 |
| Vaccine response to booster | 267 | 1152 (576-≥1448) | 262 | 362 (144–724) | 239 | 724 (228-≥1448) | 260 | 181 (72–576) | B v A, D v A, D v B, C v B: p < 0.0001 |
| Type 3 | |||||||||
| Vaccine response to primary series | 99 | 28 (11–91) | 97 | 14 (11–36) | 92 | 20 (11–144) | 196 | 91 (36–455) | B v A: p = 0.0136 D v A, D v B: p < 0.0001 C v B: p = 0.33 |
| Priming response | 171 | ≥1448 (≥1448 -≥1448) | 166 | ≥1448 (910-≥1448) | 170 | ≥1448 (724-≥1448) | - | - | B v A: p < 0.0001 C v B: p = 0.70 |
| Cumulative vaccine response | 270 | ≥1448 (≥1448-≥1448) | 263 | ≥1448 (910-≥1448) | 262 | ≥1448 (910-≥1448) | - | - | B v A: p < 0.0001 C v B: p = 0.92 |
| Vaccine response to booster | 269 | ≥1448 (1152-≥1448) | 261 | 910 (455-≥1448) | 257 | ≥1448 (576-≥1448) | 266 | 455 (144–1152) | B v A, D v A, D v B: p < 0.0001 C v B: p = 0.0010 |
Data are the number of vaccine responders (n) and the median (interquartile range) of reciprocal antibody titers among vaccine responders. Vaccine response defined as seroconversion from seronegative (<1:8) to seropositive (≥1:8) after vaccination, or a four-fold rise in antibody titers after vaccination adjusted for maternal antibody decay. Priming defined as absence of vaccine response at 22 weeks with subsequent evidence of response at 23 weeks. Cumulative vaccine response defined as vaccine response at 22 weeks or priming response at 23 weeks. IPV=inactivated poliovirus vaccines. fIPV=fractional inactivated poliovirus vaccine. Kruskal-Wallis Test was used to test for inequality of antibody titer distributions between study arms.